Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Peter Sandy, Senior Scientist at Constellation Will Give a Presentation at the 2nd Cancer Epigenetics (Nov 8-9, 2012 in Boston, MA)

GTC
Posted on: 11 Oct 12Roche
Posted on: 11 Oct 12GSK
Posted on: 11 Oct 12NOVO nordisk
Posted on: 11 Oct 12Shire
Posted on: 11 Oct 12

Peter Sandy, Senior Scientist at Constellation will give a presentation on “4SC Preclinical Evaluation of BET Bromodomain Inhibitors for the Treatment of Cancer” at the 2nd Cancer Epigenetics conference taking place on Nov 8-9, 2012 in Boston, MA.

Tumorigenesis is a multistep process that is driven by both genetic and epigenetic changes. DNA and histone tail modifications directly regulate the transcriptional machinery’s access to chromatin thereby influencing gene expression. Recently, Constellation and others have shown that pharmacological inhibition of the Bromodomain and Extraterminal domain (BET) family of chromatin readers leads to growth arrest and/or apoptosis in a panel of cell lines and results in effective tumor growth inhibition in xenograft models. In his presentation, Dr. Sandy will describe the relationship between the in vitro binding, in-cell activity, PK, PD and in vivo efficacy of different BET inhibitors developed at Constellation Pharmaceuticals. The data suggest that selective and potent BET bromodomain-inhibitors could represent a therapeutic alternative for the treatment of various hematological malignancies.

Peter Sandy, Ph.D. is a Senior Scientist at Constellation Pharmaceuticals. Dr. Sandy’s main responsibilities include: development of MOA and phenotypic cellular assays, oversee in vivo PK/PD and efficacy studies at CROs and initiate/maintain collaborations with academic investigators. Dr. Sandy joined Constellation Pharmaceuticals in early 2009. Prior to his industrial experience he was a postdoctoral associate in the laboratory of Tyler Jacks at MIT’s David H. Koch Institute for Integrative Cancer Research. His postdoctoral work included in vitro RNAi screens to identify genes that are synthetic lethal with mutant KRAS and in vivo insertional mutagenesis using the Sleeping Beauty transposon system to identify genes required for metastasis.

GTC’s 2nd Cancer Epigenetics conference, one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA, is the only cancer epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.



For more information, please visit www.gtcbio.com

For more information:
http://www.gtcbio.com/cancerepigenetics

Editor's Details

Ken Lin
GTC
http://www.gtcbio.com
6262566405
ken.lin@gtcbio.com

Last updated on: 11/10/2012

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.